Dydrogesterone treatment is associated with an increased live birth rate in RPL patients.
An increased live birth rate was found in women treated with dydrogesterone regardless of other treatments.
Several mechanisms may explain the positive effect of progesterone treatment in RPL patients. One of the most important explanations is progesterone’s immunomodulatory effect. Another possible mechanism is the presence of an abnormality in progesterone levels, affinity, or both. Dydrogesterone is known for its improved bioavailability, metabolic stability, and immunomodulation.
A retrospective cohort study was conducted on 866 patients, divided into two groups and examined: 509 women in dydrogesterone treatment group and a group of 357 patients who did not receive the treatment.
Dydrogesterone 10 mg twice daily was administered from pregnancy diagnosis till 20 weeks of gestation in the dydrogesterone treatment group.
An increased live birth rate was found in women treated with dydrogesterone regardless of other treatments.
In this analysis, advanced maternal age was clearly associated with low live birth rates and high ratio of pregnancy losses to the number of pregnancies. Therefore, it is of utmost importance to conduct evaluations as early as possible when women meet RPL criteria so that the probability of live birth will not be reduced by their advanced age.